Cancer Family
Adnexal Neoplasm
CI-CAN-00000005Explore in graph →
Non-malignant777 active trials5 approved drugs94 evidence items
- NCIt
- C212119
Loading cancer entity…
Cancer Family
CI-CAN-00000005Explore in graph →
Clinical trials
3,522 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01953159 | Assessment of Paclitaxel-Induced Neuropathy | active not recruiting | — | 43 | University of ChicagoOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT07009743 | O-RADS MRI System on Early Detection of Ovarian Cancer | active not recruiting | — | 2,549 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 8, 2025 | clinicaltrials |
| NCT05740956 | A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 318 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT05518253 | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 30 | Weijia Fang, MDOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06990503 | SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer | not yet recruiting | Phase 3 | 300 | Tongji HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06990516 | SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer | not yet recruiting | Phase 1 / Phase 2 | 90 | Tongji HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT02571725 | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | active not recruiting | Phase 1 / Phase 2 | 50 | New Mexico Cancer Research AllianceOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT04575961 | Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer(PERCEPTION) | active not recruiting | Phase 2 | 33 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06988280 | Ultrasound-guided Transvaginal Aspiration of Cystic Pelvic Lesions(UTAC) | recruiting | — | 100 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06129968 | Transforming Ovarian Cancer Diagnostic Pathways(SONATA) | recruiting | — | 34,000 | Professor Sudha SundarOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT05156892 | Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer(TICTOC) | active not recruiting | Phase 1 | 44 | Anthony Joshua, FRACPOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06972693 | NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma(PERSONA-Ovary) | active not recruiting | Phase 4 | 323 | European Institute of OncologyOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06973421 | Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 35 | Fudan UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT05179824 | Tempus Priority Study: A Pan-tumor Observational Study | active not recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT04503265 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 122 | AtlasMedx, IncorporatedINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT06940921 | SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases | active not recruiting | Phase 1 / Phase 2 | 26 | Zhang TaoOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06686030 | Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer | recruiting | Phase 2 | 150 | AkesoINDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
| NCT06925126 | Exosome-based Recurrence Score for Post-Treatment Ovarian Cancer | not yet recruiting | — | 200 | Fudan UniversityOTHER | 0 | Apr 13, 2025 | clinicaltrials |
| NCT06907771 | Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer(PACO) | recruiting | — | 130 | University Hospital, Strasbourg, FranceOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06902467 | Combined Intraperitoneal Chemotherapy Regimen After Optimal Interval Surgery in Advanced Ovarian Cancer: BICOV-1 (Bidirectional Chemotherapy in Ovarian Cancer)(BICOV) | recruiting | N/A | 20 | Fundacion para la Formacion e Investigacion Sanitarias de la Region de MurciaOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06594679 | A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)(NICHOL) | recruiting | Phase 1 / Phase 2 | 73 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06689605 | Ultrasound-guided Tru-cut Biopsy in Patients with Suspected Ovarian Cancer: Adequacy, Accuracy, Safety and Patient Assessment.(TRUCUTOC) | recruiting | — | 30 | University Hospital Hradec KraloveOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06883409 | Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer | recruiting | N/A | 33 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06890858 | A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer | recruiting | Phase 2 | 20 | Zhejiang Provincial People's HospitalOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06887933 | A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer | not yet recruiting | Phase 4 | 67 | GlaxoSmithKlineINDUSTRY | 0 | Mar 21, 2025 | clinicaltrials |
| NCT06887673 | Lipid Mediators & Cancer: Montelukast, SPM, and Almonds | not yet recruiting | Early Phase 1 | 56 | University of South FloridaOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06884345 | METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer | active not recruiting | Phase 1 / Phase 2 | 28 | Anhui Provincial Cancer HospitalOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06871787 | Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery(INOCA) | not yet recruiting | Phase 4 | 50 | Istanbul UniversityOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06324175 | Spatial Radiogenomics of Ovarian Cancer(CO-MOULD) | recruiting | — | 24 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT06331130 | Mesenteric Infiltration in Ovarian Cancer(MIO) | recruiting | — | 510 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06560112 | An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer | recruiting | Phase 2 | 172 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06635837 | Prospective Evaluation of the Role of MRI in Ovarian Masses During Pregnancy(PROM-P) | recruiting | — | 60 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT04196257 | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | recruiting | Phase 1 | 50 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06475261 | Tissue Oximetry's Measurement in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy | recruiting | — | 50 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT05704621 | Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance(SOCCER-P) | recruiting | Phase 2 | 124 | Korea University Guro HospitalOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT05953883 | Proteogenomic Signatures Analysis In Ovarian Cancer(PROGENITOR) | active not recruiting | N/A | 24 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT06085404 | Patients Derived Organoids in Ovarian Cancer(PICTURE) | recruiting | N/A | 48 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT06203106 | NYSCF Scientific Discovery Biobank | recruiting | — | 10,000 | New York Stem Cell Foundation Research InstituteOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT00005095 | Specimen and Data Study for Ovarian Cancer Early Detection and Prevention | recruiting | — | 6,000 | Northwestern UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06844136 | ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Patient Clinical Response to Administered Chemotherapy in Patients(ChemoINtel) | recruiting | — | 100 | Pierian BiosciencesINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06846424 | SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer | not yet recruiting | Phase 1 | 24 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Feb 26, 2025 | clinicaltrials |
| NCT05591131 | Genetic Testing in African Americans(GTM-I) | active not recruiting | N/A | 21 | Augusta UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06836219 | Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario(BeLIVE) | recruiting | — | 300 | Consorzio OncotechOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT06838429 | PARPi and Ovarian Cancer Survival | not yet recruiting | — | 6,000 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 0 | Feb 20, 2025 | clinicaltrials |
| NCT05104515 | First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine | recruiting | Phase 1 | 36 | Oxford Vacmedix UK Ltd.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06827353 | Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency(OVNI-B) | recruiting | — | 300 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06825455 | Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors | not yet recruiting | Early Phase 1 | 18 | Peking UniversityOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03976999 | Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers(BCBOvaire) | recruiting | N/A | 300 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 12, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2025source: clinicaltrials